Fig. 2: Tumor response to neoadjuvant therapy. | Nature Communications

Fig. 2: Tumor response to neoadjuvant therapy.

From: The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Fig. 2

a Waterfall plot of tumor regression by pathology (n = 33). b Representative radiological and pathological images (HE staining, ×40, ×200) from responsive (NP025) and nonresponsive (NP018) patients. HE staining was performed one time in 33 independent samples with similar results. c Representative pathological features (HE staining, ×200) after immunotherapy. HE staining was performed one time in 33 independent samples with similar results. CPS combined positive score, UTA unable to access, GEJ gastroesophageal junction, MPR major pathologic response, HE hematoxylin and eosin, TLS tertiary lymphoid structures, TILs tumor-infiltrating lymphocytes. Source data are provided as a Source Data file.

Back to article page